• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "肺疾病" 524 results
        • 無創正壓通氣治療慢性阻塞性肺疾病合并呼吸衰竭的護理

          【摘要】 目的 探討無創正壓通氣治療慢性阻塞性肺疾病合并呼吸衰竭的護理措施。 方法 回顧性分析2006年1月-2008年12月使用無創正壓通氣治療合并呼吸衰竭的慢性阻塞性肺疾病患者的臨床資料,比較其使用呼吸機前后的癥狀、舒適性、體溫、心率及血氣分析的變化。 結果 使用無創正壓通氣治療后患者癥狀改善,無明顯不適感,體溫、心率趨于平穩,缺氧、高碳酸血癥得到明顯改善。 結論 無創正壓通氣治療慢性阻塞性肺疾病合并呼吸衰竭易于護理,效果顯著。

          Release date:2016-09-08 09:50 Export PDF Favorites Scan
        • Acute Bronchodilator Effect of Long Term Bronchodilator Tiotropium on COPD Patients

          Objective To investigate whether long term bronchodilator tiotropium has an acute bronchodilator effect on COPD patients. Methods 46 patients with stable COPD were enrolled in the study.Lung function test was performed before and at 10 min, 20 min, 1 h after inhaling tiotropium. FEV1 , FVC,FEV1/FVC, PEF25% -75% were measured by ambulatory spirometer. The patients were followed up after 1 month.Results The mean FEV1 was ( 1. 110 ±0. 34) L before inhaling tiotropiumand ( 1. 172 ±0. 359) L, ( 1. 221 ±0. 391) L, ( 1. 225 ±0. 392) L at 10 min,20 min, 1 h after inhaling tiotropium, respectively. FEV1 at 1 h after inhaling tiotropiumsignificantly increased compared with that before inhaling tiotropium. FVC also increased and reached highest at 1 h after inhaling tiotropium. PEF25%-75% at 1 h after inhaling tiotropium increased, but there was no significance difference compared with that before inhaling tiotropium. Mean FEV1 was 1. 287 Lafter 1 month, with significant difference compared with baseline. Conclusion Tiotropium can release the symptoms and improve compliance of COPD patients for its acute bronchodilator effect on COPD patients.

          Release date:2016-09-13 03:50 Export PDF Favorites Scan
        • Single versus bilateral lung transplantation for end-stage chronic obstructive pulmonary disease: A systematic review and meta-analysis

          Objective To systematically evaluate the efficacy and safety of single and bilateral lung transplantation in the treatment of end-stage chronic obstructive pulmonary disease (COPD). Methods Chinese and English databases were searched by computer, including PubMed, Web of Science, The Cochrane Library, EMbase, CNKI, Wanfang database, VIP database and CBM. Case-control studies on single lung transplantation or bilateral lung transplantation for COPD were collected from the inception to July 31, 2022. We evaluated the quality of the literature via Newcastle-Ottawa Scale (NOS). All results were analyzed using Review Manager V5.3 and STATA 17.0. Results A total of 8 studies were included covering 14076 patients, including 8326 patients in the single lung transplantation group and 5750 patients in the bilateral lung transplantation group. NOS scores were≥6 points. The results of meta-analysis showed that there was no statistical difference in the postoperative 1-year survival between the two groups (P=0.070). The 2-year survival rate (P=0.002), 3-year survival rate (P<0.001), 5-year survival rate (P<0.001), overall survival rate (P<0.001), postoperative forced expiratory volume in one second/predicted value (P<0.001), postoperative forced vital capacity (P<0.001), and postoperative 6-minute walking distance (P=0.002) were lower or shorter than those in the bilateral lung transplantation group, the postoperative intubation time (P=0.030) was longer than that in the bilateral lung transplantation group. Bilateral lung transplantation group showed better surgical results. There was no statistical difference in the mortality, obliterative bronchiolitis, length of hospitalization, primary graft dysfunction, or postoperative adverse events (P>0.05). Conclusion Bilateral lung transplantation is associated with better long-term survival and postoperative lung function compared with single lung transplantation. In-hospital mortality and postoperative complications are similar between them.

          Release date:2024-11-27 02:45 Export PDF Favorites Scan
        • 適應性壓力通氣在慢性阻塞性肺疾病急性加重時的臨床應用

          適應性壓力通氣(APV)模式是一種能適應患者通氣需求的自動模式,即通過自動測定患者的呼吸力學參數而自動調節吸氣的壓力水平以達到目標潮氣量的目的。目前這種模式在COPD患者的應用不多。本研究通過APV與壓力支持通氣(PSV)的比較,評估APV在COPD患者急性加重期的應用效果。

          Release date:2016-09-14 11:56 Export PDF Favorites Scan
        • 慢性阻塞性肺疾病急性加重患者血清和呼出氣冷凝液中肺表面活性蛋白D與趨化因子配體18的表達及其臨床意義

          目的探索肺表面活性蛋白D (SP-D)、趨化因子配體18(CCL18)表達在慢性阻塞性肺疾病(簡稱慢阻肺)急性加重患者病情監測中的意義。 方法選取2012年4月至2013年4月慢阻肺急性加重患者22例(慢阻肺急性加重組),健康吸煙者22例(對照組)。記錄研究對象的年齡、煙齡、體重指數(BMI)、肺功能檢查結果。收集慢阻肺急性加重組治療前、后及對照組的血清和呼出氣冷凝液(EBC),采用酶聯免疫吸附試驗(ELISA)檢測各研究對象血清和EBC中SP-D、CCL18表達。分析SP-D、CCL18表達與年齡、煙齡、BMI及肺功能的相關性。 結果與對照組比較,慢阻肺急性加重組患者治療前血清及EBC中SP-D表達明顯升高[(353.1±221.7) ng/mL比(207.3±171.6) ng/mL,(2.6±1.1) ng/mL比(1.9±1.1) ng/mL,P<0.05],而治療后血清及EBC中SP-D表達比較,差異無統計學意義(P>0.05)。慢阻肺急性加重組治療前后血清和EBC中SP-D表達比較,差異無統計學意義(P>0.05)。與對照組比較,慢阻肺急性加重組治療前EBC中CCL18表達顯著降低[(14.2±5.2) pg/mL比(19.1±5.6) pg/mL,P<0.05)],而治療后EBC中CCL18表達差異無統計學意義(P>0.05);慢阻肺急性加重組治療前EBC中CCL18表達低于治療后[(14.2±5.2) pg/mL比(19.4±7.0) pg/mL,P<0.05]。各組研究對象血清中CCL18表達比較,差異均無統計學意義(P>0.05)。相關性分析結果表明:血清中SP-D表達與煙齡正相關(r=0.34,P<0.05);與第1秒用力呼氣容積(FEV1)、FEV1占預計值百分比(FEV1% pred)、用力肺活量(FVC)、FEV1與FVC比值(FEV1/FVC)負相關(r分別為-0.35、-0.34、-0.31、-0.36,P<0.05);與年齡、BMI均不相關(P>0.05)。EBC中SP-D表達與煙齡正相關(r=0.11,P<0.05);與FEV1/FVC負相關(r=-0.37,P<0.05);與年齡、BMI、FEV1、FEV1% pred、FVC均不相關(P>0.05)。血清和EBC中CCL18表達和年齡、煙齡、BMI、FEV1、FEV1% pred、FVC及FEV1/FVC均不相關(P>0.05)。 結論EBC和血清中SP-D、CCL18表達變化在慢阻肺急性加重病情監測中具有一定價值,而且EBC中SP-D、CCL18表達變化在慢阻肺急性加重患者病情監測中更具獨特的優勢。

          Release date: Export PDF Favorites Scan
        • The value of neutrophil to lymphocyte ratio in acute exacerbations of chronic obstructive pulmonary disease

          ObjectiveTo investigate the value of neutrophil/lymphocyte ratio (NLR) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) by detecting the relationship between NLR and other well-known inflammatory biomarkers.MethodsRetrospective study of 610 AECOPD cases was performed. In order to analyze the influence of NLR level on disease condition, treatment plan and prognosis, the clinical data with acute exacerbation were collected and the value of NLR in AECOPD were analyzed.ResultsThe level of NLR was higher in the group with pneumonia than that in the non-pneumonia group (P<0.05), and the more severe the pulmonary inflammation, the higher the NLR level (P<0.05). The level of NLR was higher in the group with heart failure and the group treated with ventilator and glucocorticoid (P<0.05). The NLR level was higher in the group of hospital stay over 14 days than the group of hospital stay less than 14 days (P<0.05). The NLR value of the death group was higher than that of the survival group (P<0.05). With the increase of NLR value, the mortality rate in hospital increased gradually. Compared with C-reactive protein and interleukin-6, NLR had the highest odds ratio by binary regression analysis. Cutoff value of NLR was 5.92 by analysis of receiver-operating characteristic curve with a sensitivity of 88% and a specificity of 51%, and the area under the curve in predicting in-hospital death was 0.727 (OR=4.112, 95% confidence interval 0.609 - 0.849, P=0.02).ConclusionsNLR can be used as an inflammatory marker to evaluate the severity of AECOPD and to predict the prognosis.

          Release date:2021-03-25 10:46 Export PDF Favorites Scan
        • Application value of shear wave elastography in evaluating the quadriceps femoris lesions in patients with chronic obstructive pulmonary disease

          Objective To explore the clinical value of shear wave elastography in the evaluation of quadriceps femoris lesions in patients with chronic obstructive pulmonary disease (COPD). Methods Fifty-eight COPD patients who were admitted to Chengdu First People’s Hospital and 55 healthy controls were included in the study between August 2021 and February 2022. The thickness, circumference, cross-sectional area and Young's modulus of quadriceps femoris in all subjects were measured using shear wave elastography combined with conventional two-dimensional ultrasound. The differences in ultrasound parameters between the two groups were compared, and the correlation between each ultrasound parameter and clinical evaluation indicators (modified British Medical Research Council Scale, COPD Assessment Test, six-minute walk test, and five-time sit-to-stand test) was analyzed. Results Young’s modulus values of the quadriceps femoris muscle were smaller in the COPD group than those in the healthy control group [COPD Group: rectus femoris 6.72 (6.22, 7.36) kPa, vastus medialis 6.25 (5.82, 6.79) kPa, vastus lateralis 6.94 (6.17, 7.48) kPa; healthy control group: rectus femoris 11.40 (10.23, 12.11) kPa, vastus medialis 10.77 (9.62, 11.42) kPa, vastus lateralis 11.14 (10.42, 12.52) kPa]. The differences were statistically significant (all P<0.05). The Young's modulus value of the rectus femoris muscle correlates with the aforementioned clinical evaluation indicators, with positive correlation with six-minute walk distance and negative correlation with COPD Assessment Test, modified British Medical Research Council Scale, five-time sit-to-stand time (P<0.05). Quadriceps thickness, circumference, and cross-sectional area measured by conventional two-dimensional ultrasound were not significantly different between the two groups, nor were there significant correlations between each parameter and clinical parameters (P>0.05). In addition, shear wave elastography has good reproducibility in the measurement of Young's modulus in quadriceps. Conclusions Shear wave elastography can identify quadriceps lesions earlier than conventional two-dimensional ultrasound in COPD patients, and there is a significant correlation between its measurements and the clinical condition of COPD patients. Shear wave elastography may provide a simple and noninvasive method for clinical evaluation of quadriceps femoris lesions in COPD patients.

          Release date:2022-11-29 04:54 Export PDF Favorites Scan
        • 肉芽腫性肺疾病

          肉芽腫性肺疾病( GLD) 或稱肺肉芽腫病( lung granulomatosis) , 是一組病因不同但以肉芽腫性炎癥和肉芽腫形成為共同病理特征的肺部疾病的總稱。所謂肉芽腫( granuloma) 是指巨噬細胞及其演化的細胞( 如上皮樣細胞、多核巨細胞) 聚集和增生所形成的境界清楚的結節狀病灶,是一種特殊類型的慢性增生性炎癥。肉芽腫的形成是機體對外來刺激的一種重要的防御機制, 其結果是致病因子被局限于肉芽腫內。肉芽腫不應與肉芽組織( granulation tissue)相混淆, 后者是由新生薄壁的毛細血管以及增生的成纖維細胞構成, 并伴有炎性細胞浸潤, 肉眼表現為鮮紅色, 顆粒狀,柔軟濕潤, 形似鮮嫩的肉芽故而得名, 為幼稚階段的纖維結締組織。肉芽腫性肺疾病并不是一種獨立的疾病, 病因較多, 治療上也存在很大差別, 因而如何確定其診斷極為重要。

          Release date:2016-09-13 04:06 Export PDF Favorites Scan
        • Low Molecular Weight Heparin in Treating Patients with Acute Exacerbation of COPD: A Meta-Analysis

          ObjectiveTo systematically review the clinical efficacy of low molecular weight heparin (LMWH) in treating patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). MethodsDatabases including PubMed, The Cochrane Library (Issue 10, 2013), EMbase, CBM, CNKI, VIP and WanFang Data were searched for the randomized controlled trials (RCTs) about LMWH in treating acute exacerbation of COPD from the establishment to October 2013. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality of the included studies. Meta-analysis was then performed using RevMan 5.2 software. ResultsA total of 6 RCTs involving 501 patients were finally included. The results of meta-analysis showed that:compared with the control group, LMWH significantly improved levels of D-dimmer (MD=-0.28, 95%CI-0.50 to-0.05, P=0.02), reduced carbon dioxide partial pressure (PaCO2) (MD=-3.42, 95%CI-6.66 to-0.18, P=0.04), improved coagulation (PT) (MD=1.85, 95%CI 1.29 to 2.42, P < 0.000 01), and improved clinical symptoms and signs (RR=1.33, 95%CI 1.12 to 1.58, P=0.001), but it did not improve oxygen partial pressure (PaO2) (MD=0.28, 95%CI-3.04 to 3.61, P=0.87). During treatment, no severe adverse reaction occurred in both groups. ConclusionLMWH could significantly improve symptoms caused by acute exacerbation of COPD. Due to limited quantity and quality of the included studies, the above conclusion needs to be confirmed by conducting more high quality RCTs with larger sample size.

          Release date: Export PDF Favorites Scan
        • Evaluation of Treating Patients Undergoing Open Chest Surgery with Airway Management Drugs and Moderate or Severe COPD

          ObjectiveTo evaluate the effect of airway management drugs on the respiratory function and postoperative recovery of patients who had moderate or severe chronic obstructive pulmonary diseases(COPD) undergoing an open chest surgery. MethodThere were a total of 22 patients suffering from both lung cancer, esophageal cancer or gastroesophageal junction carcinoma and moderate to severe COPD(of which there were 16 males and 6 females; accepting traditional operation 5 cases and minimally-invasive operation 17 cases; lung cancer 16 cases, esophageal cancer 4 cases and gastroesophageal junction carcinoma 2 cases as the observation group). To statistic the respiratory function and arterial blood gas analysis before and after treating with airway management drugs. And compare the postoperative pulmonary complications(PPCs) and hospital-stay with 50 patients who have no COPD(of which there were 34 males and 16 females; accepting traditional operation 17 cases and minimally-invasive operation 33 cases; lung cancer 35 cases, esophageal cancer 11 cases and gastroesophageal junction carcinoma 4 cases as the control group). ResultThere was a statistical difference of forced expiratory volume in one second(FEV1), forced vital capacity(FVC) and maximal voluntary ventilation(MVV) after the above treatment by 7 to 10 days and comparing with prior treatment(P<0.05). Partial pressure of oxygen(PaO2) increased with no statistical difference(P>0.05) while PaCO2 decreased with a statistical difference(P<0.05). Comparing with patients without COPD, the incidences of PPCs and postoperative hospital stay were of no statistical difference(P>0.05). ConclusionPatients with moderate or severe COPD with airway management drugs(antibiotics,glucocorticoids, bronchodilators and phlegm dissolving agent) in perioperative period could improve the respiratory function and operation tolerance effectively, reduce the incidence of PPCs and shorten postoperative hospital stay.

          Release date: Export PDF Favorites Scan
        53 pages Previous 1 2 3 ... 53 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜